- Home
- DOYU vs HUMA Comparison
DOYU vs HUMA Comparison
Compare DOYU & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOYU
- HUMA
- Stock Information
- Founded
- DOYU 2014
- HUMA 2004
- Country
- DOYU China
- HUMA United States
- Employees
- DOYU N/A
- HUMA N/A
- Industry
- DOYU Computer Software: Programming Data Processing
- HUMA Biotechnology: Pharmaceutical Preparations
- Sector
- DOYU Technology
- HUMA Health Care
- Exchange
- DOYU Nasdaq
- HUMA Nasdaq
- Market Cap
- DOYU 246.3M
- HUMA 250.2M
- IPO Year
- DOYU 2019
- HUMA N/A
- Fundamental
- Price
- DOYU $7.40
- HUMA $1.69
- Analyst Decision
- DOYU Hold
- HUMA Strong Buy
- Analyst Count
- DOYU 1
- HUMA 7
- Target Price
- DOYU $7.00
- HUMA $10.57
- AVG Volume (30 Days)
- DOYU 67.9K
- HUMA 6.1M
- Earning Date
- DOYU 11-19-2025
- HUMA 11-07-2025
- Dividend Yield
- DOYU 134.38%
- HUMA N/A
- EPS Growth
- DOYU N/A
- HUMA N/A
- EPS
- DOYU N/A
- HUMA N/A
- Revenue
- DOYU $586,290,301.00
- HUMA $818,000.00
- Revenue This Year
- DOYU N/A
- HUMA N/A
- Revenue Next Year
- DOYU N/A
- HUMA $1,686.52
- P/E Ratio
- DOYU N/A
- HUMA N/A
- Revenue Growth
- DOYU N/A
- HUMA N/A
- 52 Week Low
- DOYU $5.68
- HUMA $1.15
- 52 Week High
- DOYU $16.99
- HUMA $6.77
- Technical
- Relative Strength Index (RSI)
- DOYU 38.74
- HUMA 46.24
- Support Level
- DOYU $7.40
- HUMA $1.61
- Resistance Level
- DOYU $7.59
- HUMA $2.55
- Average True Range (ATR)
- DOYU 0.15
- HUMA 0.16
- MACD
- DOYU -0.03
- HUMA 0.02
- Stochastic Oscillator
- DOYU 0.00
- HUMA 3.65
About DOYU DouYu International Holdings Limited ADS
DouYu International Holdings Ltd is a game-centric live streaming platform in China and a pioneer in the eSports value chain. The company operates its platform on both PC and mobile apps, through which users can enjoy immersive and interactive games and entertainment live streaming. It generates revenues through live streaming and advertisement.
About HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.